Global imperatives and challenges facing the practice of neurology

Robert C. Griggs, MD
Bertrand Fontaine, MD, PhD
Gen Sobue, MD, PhD

Summary
The change in the practice of neurology from a diagnostic to a therapeutic specialty has empowered neurologists to make increasingly important decisions and recommendations for patients. With better understanding of disease pathogenesis and treatment has come the need to focus on disease prevention and the avoidance of treatment side effects. An increasingly automated and mechanized health care system has challenged us to integrate vast amounts of data that have a direct effect on patient risks and treatment, and to develop systems that avoid medical errors and allocate resources appropriately. It is imperative that we reaffirm the wisdom of clinical experience and judgment to inform our use of new technologies lest we lose the art of listening to and caring for the patient.

In the years since the 3 of us began to practice, our specialty has changed from a largely diagnostic to a therapy-focused discipline. And as our diagnostic skills and technologies have improved, new opportunities and challenges have confronted us. Neurologists are able to make a definitive diagnosis for most of our patients, but now have new charges: to develop the approach to presymptomatic “disease” in order to prevent predictable diseases; to decide among 2 or more treatment options; and most challenging and troubling, to decide whether a patient “deserves” expensive treatments. We must learn how...
Neurologic practice must adapt to information overload, integration of bioinformatic data, and coordination of multiple providers in an increasingly mobile society.

to contend with vast amounts of data and, in the process, yield some of our cherished autonomy to develop and implement systems of care that detect and prevent errors. The practicing neurologist has the opportunity to contribute to clinical research that will develop evidence-based neurology and quality indicators that can inform the assessments of how well we are doing as clinicians. Participation in such research serves to improve clinical skills and quality of care. Set against the almost unlimited opportunities available to neurologists is the need to develop and promote approaches that will conserve resources, so that neurologic breakthroughs are affordable.

Incidentalomas and other presymptomatic diseases
Neurologists were often the “gatekeepers” for expensive technologies such as MRI scanning and genetic testing. As test availability has expanded and associated costs have decreased, such testing may be ordered by non-neurologists before their history and examination have framed a question that the study is, ideally, designed to answer. “Disease,” such as an incidental, small tumor, unrelated to the patient’s symptoms, is often detected by MRI,1,2 and 1, 2, or more genetic diseases may be “diagnosed” by whole genome sequencing3,4 at a time when there is as yet no evidence for symptoms (or treatments). Protecting patients from unnecessary “treatment” and from disclosure of such information to employers, insurance agencies, and others is an increasing challenge. Moreover, in such situations the neurologist’s challenge is often to convince the patient and referring physician that the finding is not relevant to the patient’s symptoms (difficult) or that the actual diagnosis is a disease process invisible by imaging or undetectable by molecular testing (sometimes virtually impossible). The old adage, “never order a test until you’ve decided what it will show” still guides neurologists but is alien territory to our non-neurologist colleagues.

Disease prevention
We already know how to prevent some neurologic diseases. Examples include many infectious diseases; stroke by primary and secondary prevention; anticonvulsant adverse effects, by testing for genetic risk factors; and traumatic brain injury by appropriate protection strategies. As we learn more about the environmental factors that trigger or accelerate genetic diseases we will soon have the ability to delay or prevent the development of these diseases. Eventually, gene-based therapies will enable us to prevent or delay the onset of malignancies, metabolic disorders, and many degenerative diseases.

Challenges for disease prevention
We know how to prevent vascular diseases of the heart and brain.5 Preventing atherosclerosis in patients who have not had a stroke (primary prevention) is the responsibility of all physicians but not the specific purview of neurologists. Preventing the progression of vascular disease and recurrent stroke in a patient who has had a brain infarction is the neurologist’s job (secondary prevention). We have recognized this; we have examined how well we have done at
implementing secondary prevention strategies, but we have only begun to think about how we change patient behaviors to adopt a healthier lifestyle. The current American Heart Association (AHA) campaign to promote “Life’s Simple Seven” (table) is currently championed by AHA President and neurologist Ralph Sacco, MD, FAAN. Dr. Sacco has emphasized that only 1 in 200 people in the United States actually adopt these guidelines and change their lifestyle. The challenge for neurologists is not only that of changing patient behavior but also changing physician behavior (neurologist and primary care physicians) to focus on and learn how to improve our success at secondary stroke prevention. Primary care physicians have invested in research on ways to change physician and patient behavior and to implement the approaches that work, and translated those results into reimbursement and recommendations and standards for patient care. Neurologists are just beginning to recognize and accept the challenge.

### Addressing health care disparities

Our 3 countries—the United States, France, and Japan—have excellent but different health care systems. However, within the United States and France there are segments of society that differ widely in their access to and implementation of neurologic treatments. Looking at the neurologic care in low income countries in Africa, South America, and Asia, standard treatments for many neurologic diseases have not reached most of the population. Current world leaders of neurology have recognized and begun to focus on improving this situation. Moreover, the next generation of neurologists has tackled the challenges of going to low income areas to assess directly and begin to address the neurologic health care needs. The subspecialty of “international” or “global neurology” is a large and growing interest of medical students and residents entering our field. Our countries have the responsibility to help create the approaches and resources that will support their interests.

### Practice guidelines, quality indicators, and patient outcomes

The neurologist has always been the specialist that can listen to a patient’s history and arrive at a diagnosis that eluded other physicians. The advent of new diagnostic tests has made this skill even more important even as they have made it possible to identify previously undetectable lesions or diseases. Clinical acumen and intuition have been our survival skill. However, we now confront an increasingly well-informed and sometimes hostile public who demand that we standardize diagnostic testing, develop treatment algorithms, and pursue “evidence-based medicine” to the exclusion of less standardized treatments. The American Academy of Neurology has committed to the development of practice guidelines to standardize treatment of as many neurologic diseases as possible and is rapidly introducing quality indicators for common diseases such as epilepsy, stroke, and Parkinson disease. These quality indicators will

<table>
<thead>
<tr>
<th>Table Primary prevention of stroke: Life’s Simple Seven</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Never smoked or quit more than 1 year ago</td>
</tr>
<tr>
<td>2. Body mass index less than 25 kg/m²</td>
</tr>
<tr>
<td>3. Physical activity at least 150 minutes (moderate intensity) or 75 minutes (vigorous) each week</td>
</tr>
<tr>
<td>4. Four to 5 key components of a healthy diet consistent with American Heart Association guidelines</td>
</tr>
<tr>
<td>5. Total cholesterol &lt;200 mg/dL</td>
</tr>
<tr>
<td>6. Blood pressure &lt;120/80 mm Hg</td>
</tr>
<tr>
<td>7. Fasting blood glucose &lt;100 mg/dL</td>
</tr>
</tbody>
</table>

soon be integrated and coordinated with outcome measures that assess our ability to give optimal care. This prospect is not appealing to physicians in general and neurologists in particular. Physicians resist efforts to standardize care despite evidence that the introduction of checklists improve patient outcomes13 and that reporting comparative data on outcomes improves patient survival.14

**Systems engineering of medicine**
The prevention of errors in practice has now become a focus of the American Academy of Neurology’s energies. The development and engineering of standardized systems has enabled the airline industry to reduce errors and plane crashes dramatically.15 While patients are not airplanes, physicians are not airline pilots, and hospitals are not airports, the arguments for developing systematic approaches to error prevention are compelling. Neurologic practice must adapt to information overload, integration of bioinformatic data, and coordination of multiple providers in an increasingly mobile society.

**Deciding when and whom to treat**
Will we be able to afford the new treatments for neurologic diseases? There is a major difference in the costs of health care in the United States, France, and Japan. The United States spends 16% of GDP on health care, a percentage that is increasing rapidly, while France and Japan spend less. Their costs, as ours, are becoming unaffordable. In the United States, up to 31% of the health care dollar goes to the for-profit segment of health care16 and as much as 10% may be devoted to prevention of tort actions.17 However, even if these costs can be reduced, the relentless increase in health care costs will likely become unsustainable. Expensive treatments such as IV immunoglobulin for neuromuscular diseases are beginning to be subject to standardized guidelines for use that control payment in France and Japan.18 Such prioritization of resource allocation is obviously essential, and will need to include discontinuation of medications when they are no longer effective. The practicing neurologist will also need to focus on other steps to control costs: 1) avoiding unnecessary testing; 2) devising lower cost care systems that prevent or shorten expensive in-hospital care; and 3) basing treatment decisions on metrics that reflect patient quality of life and avoiding futile but expensive interventions. As we have become skilled at treating diseases we have also created an increasing number of resource-intensive, less able people. Providing for these persons imposes still another cost on society, even though these costs are not considered “health care.”

**Training the next generation of practicing neurologists**
It remains of the greatest importance for senior clinician/educators to teach the next generation the skill of listening to the patient and letting the history and examination tell us the diagnosis. This must be coupled with the ability to question the relevance of unpredicted laboratory findings to the patient’s problems. The next generation also needs to be trained in clinical research methods, in communication skills, and in cost/benefit decision-making. Practicing neurologists (and their patients) benefit from participation in clinical research in many ways: 1) participation in trials contributes to the care of patients with conditions for which there are still suboptimal treatment options; 2) involvement in research serves to make the investigator familiar with advances in the field; 3) the quality of patient care is improved when the physician is involved in clinical research; and 4) the funding of the research often subsidizes the poorly reimbursed cognitive care that makes up the bulk of a neurologist’s practice.
Current and future residents will be sufficiently sophisticated in information technology that they will have relatively little difficulty making optimum use of the electronic health record and adapting to the system engineering it will facilitate. But they, like we ourselves, will need constant reminders that what patients crave is an attentive listener, focused on them as a person, tailoring treatment and advice to their specific complaints. As argued passionately and eloquently by AAN past-President Steve Sergay, “…doctoring faces many challenges…, all potentially imperiling our professional soul or ethos of life as doctors.” Dr. Sergay further asserts that, “We must return our principal attention to humanity to ensure that ill humans will always be more than integers on an economic chart.” This advice from the consummate practicing neurologist cannot be overemphasized.

REFERENCES

DISCLOSURES
Dr. Griggs serves as Chair of the Executive Committee of the Muscle Study Group, which receives support from pharmaceutical companies; has served on scientific advisory boards for The National Hospital Queen Square and PTC Therapeutics, Inc.; serves on the editorial boards of NeuroTherapeutics and Current Treatment Opinions in Neurology and as Correspondence Editor for Neurology®; is immediate Past President of the American Academy of Neurology; receives royalties from the publication of Andreoli and Carpenter’s Cecil Essentials of Medicine, Eighth Edition (W.B. Saunders Company, 2000,
2004, 2007, and 2010) and *Cecil Textbook of Medicine, 24th Edition* (Saunders, 2000, 2004, 2008, and 2010, in press); and has received research support from Taro Pharmaceuticals and the NIH/NINDS, the FDA, and the Muscular Dystrophy Association. Dr. Fontaine serves on the editorial board of *Gene and Immunity* and receives research support from sanofi-aventis, Institut National de la Santé et de la Recherche Médicale, Association Française contre les Myopathies, and Association pour la Recherche sur la Sclérose en Plaques. Dr. Sobue has served on scientific advisory boards for Kanae Science Foundation for the Promotion of Medical Science and Naito Science Foundation; serves on the advisory board of *Brain* and the editorial board of *Degenerative Neurological and Neuromuscular Disease*; and receives research support from the Ministry of Education, Culture, Sports, Science and Technology of Japan, the Ministry of Welfare, Health and Labor of Japan, and the Japan Science and Technology Agency, Core Research for Evolutional Science and Technology.

### Related articles from other AAN physician and patient resources

**Neurology®**  ●  [www.neurology.org](http://www.neurology.org)

**Doctoring 2009: Embracing the challenge.**
October 13, 2009; 73:1234–1239.

**Global Perspectives.**
October 18, 2011; 77:1565–1567.

**Patient Page: The neurology world is flat.**

**Neurology Now®**  ●  [www.neurologynow.org](http://www.neurologynow.org)

Global Neurology Podcasts.

**Neurology Today®**  ●  [www.neurotodayonline.com](http://www.neurotodayonline.com)

October 6, 2011; 11:43–45.

Global Neurology: Dr. Michael Earnest: On building health and the community in rural Haiti.
October 6, 2011; 11:43–44.

Global Neurology: Mateja de Leonni Stanonik, MD, PhD: Telemedicine pioneer and Slovenia’s first Surgeon General.
September 1, 2011; 11:17–18.

Global Neurology Podcasts.